These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 23140169)

  • 1. Potential benefits of cyproheptadine in HIV-positive patients under treatment with antiretroviral drugs including efavirenz.
    Dabaghzadeh F; Khalili H; Ghaeli P; Dashti-Khavidaki S
    Expert Opin Pharmacother; 2012 Dec; 13(18):2613-24. PubMed ID: 23140169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyproheptadine for prevention of neuropsychiatric adverse effects of efavirenz: a randomized clinical trial.
    Dabaghzadeh F; Ghaeli P; Khalili H; Alimadadi A; Jafari S; Akhondzadeh S; Khazaeipour Z
    AIDS Patient Care STDS; 2013 Mar; 27(3):146-54. PubMed ID: 23442031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of concomitant use of montelukast and efavirenz on neuropsychiatric adverse events.
    Ibarra-Barrueta O; Palacios-Zabalza I; Mora-Atorrasagasti O; Mayo-Suarez J
    Ann Pharmacother; 2014 Jan; 48(1):145-8. PubMed ID: 24259633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efavirenz and the CNS: what we already know and questions that need to be answered.
    Apostolova N; Funes HA; Blas-Garcia A; Galindo MJ; Alvarez A; Esplugues JV
    J Antimicrob Chemother; 2015 Oct; 70(10):2693-708. PubMed ID: 26203180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse Neuropsychiatric Events and Recreational Use of Efavirenz and Other HIV-1 Antiretroviral Drugs.
    Dalwadi DA; Ozuna L; Harvey BH; Viljoen M; Schetz JA
    Pharmacol Rev; 2018 Jul; 70(3):684-711. PubMed ID: 29945900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurological and psychiatric tolerability of rilpivirine (TMC278) vs. efavirenz in treatment-naïve, HIV-1-infected patients at 48 weeks.
    Mills AM; Antinori A; Clotet B; Fourie J; Herrera G; Hicks C; Madruga JV; Vanveggel S; Stevens M; Boven K;
    HIV Med; 2013 Aug; 14(7):391-400. PubMed ID: 23298380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of trials investigating efavirenz-induced neuropsychiatric side effects and the implications.
    Gaida R; Truter I; Grobler C; Kotze T; Godman B
    Expert Rev Anti Infect Ther; 2016; 14(4):377-88. PubMed ID: 26900637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Valerian in Preventing Neuropsychiatric Adverse Effects of Efavirenz in HIV-Positive Patients: A Pilot Randomized, Placebo-Controlled Clinical Trial.
    Ahmadi M; Khalili H; Abbasian L; Ghaeli P
    Ann Pharmacother; 2017 Jun; 51(6):457-464. PubMed ID: 28478716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuropsychiatric symptoms associated with efavirenz: prevalence, correlates, and management. A neurobehavioral review.
    Muñoz-Moreno JA; Fumaz CR; Ferrer MJ; González-García M; Moltó J; Negredo E; Clotet B
    AIDS Rev; 2009; 11(2):103-9. PubMed ID: 19529750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring.
    Gutiérrez F; Navarro A; Padilla S; Antón R; Masiá M; Borrás J; Martín-Hidalgo A
    Clin Infect Dis; 2005 Dec; 41(11):1648-53. PubMed ID: 16267739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients.
    Neukam K; Mira JA; Ruiz-Morales J; Rivero A; Collado A; Torres-Cornejo A; Merino D; de Los Santos-Gil I; Macías J; González-Serrano M; Camacho A; Parra-García G; Pineda JA;
    J Antimicrob Chemother; 2011 Nov; 66(11):2605-14. PubMed ID: 21903660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implications of efavirenz for neuropsychiatry: a review.
    Cavalcante GI; Capistrano VL; Cavalcante FS; Vasconcelos SM; Macêdo DS; Sousa FC; Woods DJ; Fonteles MM
    Int J Neurosci; 2010 Dec; 120(12):739-45. PubMed ID: 20964556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of neuropsychiatric adverse events during 12 weeks of treatment with etravirine and efavirenz in a treatment-naive, HIV-1-infected population.
    Nelson M; Stellbrink HJ; Podzamczer D; Banhegyi D; Gazzard B; Hill A; van Delft Y; Vingerhoets J; Stark T; Marks S
    AIDS; 2011 Jan; 25(3):335-40. PubMed ID: 21150563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of neuropsychiatric adverse events during clinical trials of efavirenz in antiretroviral-naive patients: a systematic review.
    Gazzard B; Balkin A; Hill A
    AIDS Rev; 2010; 12(2):67-75. PubMed ID: 20571601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuropsychiatric adverse events after switching from an antiretroviral regimen containing efavirenz without tenofovir to an efavirenz regimen containing tenofovir: a report of nine cases.
    Allavena C; Le Moal G; Michau C; Chiffoleau A; Raffi F
    Antivir Ther; 2006; 11(2):263-5. PubMed ID: 16640107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiviral efficacy, tolerability and pharmacokinetics of efavirenz in an unselected cohort of HIV-infected children.
    Wintergerst U; Hoffmann F; Jansson A; Notheis G; Huss K; Kurowski M; Burger D
    J Antimicrob Chemother; 2008 Jun; 61(6):1336-9. PubMed ID: 18343800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality of life and depression among HIV-infected patients receiving efavirenz- or protease inhibitor-based therapy in Senegal.
    Poupard M; Ngom Gueye NF; Thiam D; Ndiaye B; Girard PM; Delaporte E; Sow PS; Landman R
    HIV Med; 2007 Mar; 8(2):92-5. PubMed ID: 17352765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma concentrations of efavirenz are associated with body weight in HIV-positive individuals.
    Poeta J; Linden R; Antunes MV; Real L; Menezes AM; Ribeiro JP; Sprinz E
    J Antimicrob Chemother; 2011 Nov; 66(11):2601-4. PubMed ID: 21890538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Apropos of atypical melancholia with Sustiva (efavirenz)].
    Lang JP; Halleguen O; Picard A; Lang JM; Danion JM
    Encephale; 2001; 27(3):290-3. PubMed ID: 11488260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV and mental illness in Malawi and the neuropsychiatric sequelae of efavirenz.
    Drury A; Gleadow-Ware S; Gilfillan S; Ahrens J
    Malawi Med J; 2018 Mar; 30(1):40-45. PubMed ID: 29868159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.